• In late April 2026, Humana Inc. reported first-quarter 2026 results showing revenue rising to US$39.65 billion from US$32.11 billion a year earlier, while net income eased to US$1.19 billion and diluted EPS from continuing operations slipped to US$9.83.
• At the same time, Humana completed a US$276.13 million buyback of 1,200,726 shares and lowered its 2026 GAAP diluted EPS guidance to at least US$8.36, highlighting that higher sales are not fully translating into earnings growth.
• Next, we’ll examine how Humana’s lower full-year earnings guidance, despite strong revenue growth, affects the company’s existing investment narrative.

AI is about to change healthcare. These 32 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10b in market cap - there's still time to get in early.

Humana Investment Narrative Recap

To own Humana, you need to believe its Medicare Advantage focus, value based care push, and CenterWell expansion can translate strong enrollment and revenue into durable earnings, despite regulatory and cost pressures. The latest results show revenue rising but earnings and 2026 EPS guidance easing, which reinforces that the most important near term catalyst remains margin stabilization, while the biggest current risk is that higher utilization and policy uncertainty prevent that margin story from improving. Overall, this news supports rather than changes that tension.

The completed US$276.13 million repurchase of 1,200,726 shares in early 2026 stands out here. Against lower full year EPS guidance, the buyback underscores that Humana is still returning capital while working through margin headwinds. For investors focused on earnings quality and the impact of medical cost trends, this combination of weaker guidance and continued buybacks brings the timing and sustainability of any future margin recovery into sharper focus.

Yet, even with strong revenue growth, investors should be aware that the real pressure point is...

Humana's narrative projects $184.2 billion revenue and $3.1 billion earnings by 2029.

Uncover how Humana's forecasts yield a $210.46 fair value, a 29% downside to its current price.

Exploring Other Perspectives

Some of the lowest rated analysts already expected slower progress, with revenue around US$129.7 billion and earnings of about US$2.4 billion by 2028, so this guidance cut could push their more cautious Medicare Advantage margin concerns even further, reminding you that views on Humana’s risk and reward can differ widely and are likely to keep evolving as new results arrive.

Explore 9 other fair value estimates on Humana - why the stock might be worth 43% less than the current price!

Reach Your Own Conclusion

Don't just follow the ticker - dig into the data and build a conviction that's truly your own.

• A great starting point for your Humana research is our analysis highlighting 2 key rewards and 2 important warning signs that could impact your investment decision.
• Our free Humana research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Humana's overall financial health at a glance.

No Opportunity In Humana?

The market won't wait. These fast-moving stocks are hot now. Grab the list before they run:

• Capitalize on the AI infrastructure supercycle with our selection of the 38 best 'picks and shovels' of the AI gold rush converting record-breaking demand into massive cash flow.
• Find 45 companies with promising cash flow potential yet trading below their fair value.
• Outshine the giants: these 15 early-stage AI stocks could fund your retirement.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.